Best BPC-157 Oral Supplements: ProHealth’s Triple-Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026

Best BPC-157 Oral Supplements: ProHealth’s Triple-Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026




Best BPC-157 Oral Supplements: ProHealth’s Triple-Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026

36-Year Company’s Oral Capsule Format vs. Injectable BPC-157: Third-Party Lab Testing, Bioavailability Questions, and Regulatory Status Examined

CARPINTERIA, Dec. 23, 2025 (GLOBE NEWSWIRE) — This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. This article is for informational purposes only and does not constitute medical advice. BPC-157 is a research-stage peptide without extensive human clinical trials. Always consult a qualified healthcare professional before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Best BPC-157 Oral Supplements ProHealth's Triple-Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026

If you’re here because you saw a peptide ad and then searched “best oral BPC-157,” the skepticism is healthy. BPC-157 is still a research-stage compound with limited human clinical evidence, so the only responsible way to evaluate a product like this is to separate (1) what the company discloses and can document (testing, formulation, policies) from (2) what preclinical research suggests in animals or lab settings, and (3) what remains unproven in humans. This article walks through those layers so readers can decide—without hype—whether this category even belongs in their wellness plan.

Social media feeds show growing interest in peptide therapy this holiday season, and BPC-157 has emerged as one of the most discussed compounds in the longevity and recovery supplement space. As people search for “ProHealth BPC-157 review” and “is ProHealth BPC-157 legit” following ad exposure, one question dominates: How do you evaluate quality and legitimacy in a market flooded with unverified peptide products?

ProHealth Longevity, a supplement company with over 36 years of operation and an A+ Better Business Bureau rating, has entered the oral BPC-157 market. According to the company’s website, ProHealth BPC-157 is described as containing 500mcg of what the company characterizes as pharmaceutical-grade BPC-157 in arginate salt form, with pricing listed on the product page and subject to change.

This analysis examines what ProHealth discloses about testing and formulation, what the preclinical research actually indicates about BPC-157, how oral delivery compares to injectable protocols, and what evaluation criteria matter when assessing products in this research-stage category.

What Is ProHealth Longevity? Company Background and Legitimacy Verification

Before evaluating any peptide supplement, establishing company legitimacy is essential. The peptide market has seen an influx of new vendors over the past 24 months, many with minimal track records and questionable quality standards. ProHealth Longevity presents a different profile.

Founded in 1988, ProHealth has operated in the supplement industry for 36 years—significantly longer than most peptide-specific vendors that have emerged recently. According to the Better Business Bureau, the company maintains an A+ rating, a designation that requires sustained customer satisfaction and ethical business practices over extended periods. ProHealth is based in Carpinteria, California, with verifiable contact information including phone lines staffed Monday through Friday, 8am to 5pm Pacific Time.

The company’s evolution into peptide supplementation represents an extension of its existing focus on longevity and cellular health products, including NAD+ boosters like NMN and Nicotinamide Riboside. According to company materials, the company describes its manufacturing as occurring in FDA-registered, GMP-certified facilities in the United States, adhering to what the company characterizes as pharmaceutical-grade production standards even for dietary supplements.

What distinguishes ProHealth’s approach in the peptide category, according to the company, is a triple third-party lab testing protocol. The company states that each batch of BPC-157 undergoes independent verification for identity, purity, and potency at three separate laboratories. According to company disclosures, this testing screens for contaminants including heavy metals, microbial pathogens, and residual solvents. The company makes Certificates of Authenticity viewable by customers, providing transparency uncommon in the peptide supplement space where many products rely solely on manufacturer claims.

For customers researching “is ProHealth BPC-157 legit,” these verifiable factors—decades of operation, BBB rating, transparent contact information, and independent lab testing—provide objective legitimacy markers beyond marketing claims. For complete company history and quality standards, view the current ProHealth BPC-157 offer (official ProHealth page).

What Is BPC-157? Understanding the Research-Stage Peptide

BPC-157, or Body Protection Compound 157, is a synthetic 15-amino acid peptide sequence derived from a protective protein naturally occurring in human gastric juice. The compound was originally studied in preclinical research for its potential gastric protective properties, with early animal model studies examining its effects on stomach lining integrity.

Over the past two decades, preclinical research has expanded to investigate BPC-157’s potential effects on various tissue types beyond the gastrointestinal system. Laboratory studies using animal models have explored mechanisms including angiogenesis (new blood vessel formation), modulation of inflammatory pathways, and cellular processes in tendons, ligaments, muscles, and connective tissues. These are animal model findings. Human clinical evidence remains limited.

It is critical to understand what BPC-157 is NOT: It is not an FDA-approved drug. It is not a medication with established clinical dosing protocols. It does not have extensive human clinical trial data demonstrating safety and efficacy for specific medical conditions. BPC-157 exists in a regulatory category as a dietary supplement ingredient, meaning it can be legally sold for general wellness purposes but cannot be marketed to treat, cure, or prevent diseases.

What the Research Suggests vs. What Remains Unproven:

Animal Studies: Laboratory research using rodent models has examined tissue processes, inflammatory responses, and biological mechanisms. These studies have shown effects in controlled animal settings but do not directly translate to guaranteed human outcomes.

In Vitro Studies: Test tube and cell culture research examining how BPC-157 interacts with cellular pathways, growth factors, and signaling molecules.

Limited Human Data: Very few human clinical trials exist, and those that do are generally small-scale, preliminary investigations. The peptide therapy community relies heavily on animal model data when discussing potential applications, but this creates significant gaps in understanding human safety, dosing, and effectiveness.

According to preclinical research published in peer-reviewed journals, BPC-157 has been studied for its potential interactions with several biological pathways in animal models:

VEGF (Vascular Endothelial Growth Factor) Pathway: Animal studies suggest BPC-157 may interact with angiogenesis pathways. Human relevance unproven.

Inflammatory Modulation: Laboratory research indicates BPC-157 may interact with inflammatory signaling pathways in controlled settings. Human clinical applications remain unestablished.

Collagen and Tissue Processes: Some preclinical studies have examined whether BPC-157 influences biological processes in connective tissues in animal models. Translation to human tissue outcomes is not demonstrated.

Gut-Associated Pathways: Given its origin as a gastric protective compound in animal research, studies have explored potential effects in laboratory models. Human gut applications lack clinical trial support.

This is ingredient-level research; ProHealth BPC-157 as a finished product has not been clinically studied in humans. The preclinical findings are promising enough to generate interest in the longevity and athletic performance communities, but they do not constitute proof of specific outcomes in any individual human user.

Anyone considering BPC-157 must understand they are exploring a research-stage compound with limited human safety data, not a proven medical treatment. ProHealth publishes detailed information about their arginate salt formulation and oral delivery advantages on the official product page (official ProHealth page).

The Oral vs. Injectable Question: Addressing the Primary Objection

For individuals researching “does oral BPC-157 work,” this section addresses the most significant technical question surrounding ProHealth’s product: Can a peptide traditionally administered via injection be effective when taken orally?

Historically, most peptides have been considered ineffective when swallowed because digestive enzymes in the stomach and small intestine break down protein structures before they can be absorbed. This is why insulin, growth hormone, and many other peptide-based medications require injection—oral administration would result in degradation before the compound reaches systemic circulation.

BPC-157 presents unique considerations in this regard. According to the company, the arginate salt form of BPC-157 has been studied for its potential stability in acidic gastric environments. Unlike some peptides that are immediately destroyed by stomach acid, research suggests the arginate salt formulation may maintain structural integrity long enough to pass through the stomach. However, human bioavailability data for oral BPC-157 is not established through published pharmacokinetic studies.

Several factors support the theoretical viability of oral BPC-157, though human outcomes remain unproven:

Gastric Stability: BPC-157 was originally studied for gastric protection in animal models, meaning the compound was administered directly into the stomach in research settings. This suggests inherent stability in acidic environments that many other peptides lack, according to preclinical findings.

Local GI Effects: For applications related to gut lining, oral administration may provide direct topical contact with intestinal tissues in theory. Clinical evidence for this mechanism in humans is limited.

Arginate Salt Formulation: The arginate salt form has been studied for enhanced stability compared to the acetate salt form commonly used in injectable preparations in laboratory settings. The company’s choice of arginate salt reflects this research literature.

Precedent in Animal Research: Multiple animal model studies have used oral administration of BPC-157, demonstrating biological effects through this route in controlled laboratory conditions. Animal physiology differs significantly from humans, limiting direct translation.

However, honest evaluation requires acknowledging the limitations and unknowns:

Bioavailability Uncertainty: The percentage of orally administered BPC-157 that reaches systemic circulation in humans is not definitively established through published pharmacokinetic studies. Injectable administration likely achieves higher blood concentrations, though comparative human data does not exist.

Dosing Equivalency Unknown: There is no established conversion factor between oral and injectable dosing based on human clinical trials. Injectable users typically administer 250-500mcg twice daily (500-1000mcg total). The company recommends 500mcg once daily orally. Whether these are equivalent in biological effect is not proven through comparative human studies.

Individual Variation: Factors including stomach acid levels, digestive enzyme activity, gut health status, and absorption capacity vary significantly between individuals, potentially affecting oral BPC-157 effectiveness differently for different users.

Practical Considerations Favoring Oral Delivery:

Beyond bioavailability questions, oral administration offers significant lifestyle advantages that make peptide therapy accessible to a broader population:

No Injection Requirement: Many individuals interested in tissue support supplementation are deterred by injection protocols. Fear of needles, concerns about sterile technique, discomfort, and the psychological barrier of self-injection all limit adoption of injectable peptides.

Convenience: Once-daily oral dosing integrates seamlessly into existing supplement routines. No refrigeration, measuring, or drawing doses required.

Travel Compatibility: Capsules travel easily without concerns about maintaining cold chain, carrying syringes through security, or finding private space for injections.

Lower Barrier to Entry: Oral peptides allow individuals to explore tissue support supplementation without committing to injection protocols, making it appropriate for peptide therapy beginners.

Regulatory Simplicity: As a dietary supplement, oral BPC-157 does not require prescriptions, medical consultations, or relationships with compounding pharmacies that characterize many injectable peptide protocols.

Who Each Format May Suit:

Oral BPC-157 May Be Preferable For:

  • Individuals needle-averse or injection-hesitant
  • Those seeking convenient once-daily supplementation
  • Peptide therapy beginners exploring the category
  • People with active travel schedules
  • Those primarily interested in gut health applications (topical GI contact)
  • Individuals preferring established supplement companies over gray-market sources

Injectable BPC-157 May Be Preferable For:

  • Experienced peptide users comfortable with injection protocols
  • Those working with knowledgeable practitioners providing dosing guidance
  • Individuals seeking maximum potential bioavailability
  • People with access to quality compounding pharmacies
  • Users able to maintain twice-daily injection schedules

Neither format is objectively superior for all users. The choice depends on individual priorities regarding convenience, bioavailability optimization, comfort with administration methods, and integration with existing health routines.

Who Uses BPC-157? Understanding the Peptide-Curious Population

The individuals exploring BPC-157 supplementation span diverse backgrounds, ages, and health goals, but common themes emerge in the peptide-curious population:

Active Adults Experiencing Recovery Challenges: Many BPC-157 users are individuals in their 40s, 50s, and 60s who maintain active lifestyles but notice their bodies no longer recover as quickly from physical stress. Weekend warriors, recreational athletes, and fitness enthusiasts who train consistently often find that nagging injuries that would have resolved in weeks now persist for months. These individuals are not seeking to treat diagnosed medical conditions but rather to support their body’s natural repair processes as they age.

Athletes Managing Chronic Overuse Issues: CrossFit athletes, runners, cyclists, tennis players, and individuals in high-volume training programs frequently develop chronic tendon and ligament issues from repetitive stress. Physical therapy, rest, and conventional approaches provide some relief but often fail to fully resolve stubborn injuries. These athletes explore peptide therapy as a tool to support tissue resilience while continuing to train at their desired intensity.

Individuals With Persistent Gut Health Concerns: People struggling with irritable bowel syndrome, suspected leaky gut, food sensitivities, or digestive discomfort that has not responded adequately to probiotics, elimination diets, or conventional gastroenterology approaches sometimes explore BPC-157 based on its original research focus on gastric protection and gut lining integrity.

Longevity and Biohacking Community Members: Individuals following longevity researchers like Peter Attia, Andrew Huberman, David Sinclair, and Rhonda Patrick often take a proactive approach to cellular health optimization. This population already uses NAD+ boosters, practices time-restricted eating, tracks biomarkers, and views cutting-edge supplementation as part of a comprehensive healthspan extension strategy.

Post-Surgical Recovery Seekers: Some individuals recovering from orthopedic surgeries, abdominal procedures, or other interventions explore tissue support peptides as adjuncts to their medical recovery protocols, though this should only occur with physician awareness and approval.

Peptide Therapy Beginners: A significant portion of the oral BPC-157 market consists of people who have read about peptide therapy but have been deterred by injection requirements. Oral delivery provides an entry point to explore the category without the commitment and technical demands of injectable protocols.

What unites these diverse users is a shared frustration: conventional approaches have provided incomplete results, and they are willing to explore research-stage compounds in pursuit of better tissue support and recovery optimization. To review ProHealth BPC-157 specifications, third-party lab certificates, and current subscription options, view the current ProHealth BPC-157 offer (official ProHealth page).

Self-Assessment Framework: Is ProHealth BPC-157 Right for You?

Rather than presenting testimonials or making outcome guarantees, the most helpful approach for potential users is a self-qualification framework. This allows individuals to assess alignment between their specific circumstances and what ProHealth BPC-157 offers.

ProHealth BPC-157 May Align Well With People Who:

Experience Nagging Joint or Tendon Issues Unresponsive to Conventional Approaches: If you have tried physical therapy, rest, anti-inflammatory medications, and conventional supplements like glucosamine or collagen without achieving full resolution, exploring a research-stage peptide with preclinical tissue-related data represents a logical next step in your wellness journey.

Want to Explore Peptide Therapy Without Injection Commitment: Many people are intrigued by the preclinical research on BPC-157 but unwilling to commit to twice-daily injections, refrigeration requirements, and sterile technique. If the injection barrier has prevented you from trying peptide therapy, oral delivery removes that obstacle while still allowing you to explore tissue support supplementation.

Value Third-Party Lab Testing and Quality Verification Standards: In a market flooded with questionable peptide sources, some consumers prioritize verification. If you are willing to explore products from established companies with independent lab testing and transparent quality standards, ProHealth’s approach aligns with your priorities.

Prefer Established Companies Over Peptide Startups: The peptide supplement space includes numerous vendors that launched in the past 2-3 years with minimal operational history. If you prefer purchasing from companies with decades of operation, Better Business Bureau ratings, and verifiable track records, ProHealth’s 36-year history differentiates it from newer entrants.

Are Building a Recovery-Focused Supplement Protocol: If you already use supplements like collagen peptides, omega-3 fatty acids, curcumin, or other recovery-supporting compounds and want to explore synergistic additions, BPC-157 fits logically into a comprehensive tissue support stack.

Need Convenient Once-Daily Oral Dosing That Fits Busy Lifestyles: Professionals with demanding schedules, frequent travelers, and individuals who struggle to maintain complex supplement regimens benefit from products that integrate seamlessly into existing routines. A single capsule taken once daily requires minimal lifestyle disruption.

Are Interested in Gut Health Applications: Given BPC-157’s origins in gastric protection research, individuals specifically seeking gut lining support may value the topical gastrointestinal contact provided by oral administration, regardless of systemic absorption questions.

Other Options May Be Preferable For People Who:

Seek FDA-Approved Treatments for Diagnosed Medical Conditions: BPC-157 is a dietary supplement, not an FDA-approved medication. If you have been diagnosed with specific medical conditions requiring treatment, working with healthcare providers to implement evidence-based medical interventions remains the appropriate path.

Require Immediate Acute Injury Intervention: Research-stage peptides are not appropriate for acute injuries requiring immediate medical attention. Fractures, severe sprains, acute ligament tears, and other traumatic injuries require evaluation and treatment by qualified medical professionals.

Prefer Injectable Peptides Based on Personal Research and Practitioner Guidance: Some individuals, after thorough research and consultation with knowledgeable practitioners, conclude that injectable BPC-157 better aligns with their goals due to potential bioavailability advantages. This is a legitimate choice based on individual circumstances and risk-benefit analysis.

Have Severe Chronic Conditions Requiring Medical Supervision Beyond Supplements: If you are managing serious chronic health issues, your care should be directed by qualified healthcare providers rather than self-directed supplementation. Supplements can potentially complement medical treatment but should not replace it.

Are Not Prepared to Commit to 4-8 Week Consistent Use: Tissue repair and cellular adaptation processes occur over weeks to months, not days. If you are seeking immediate results or are unlikely to maintain consistent daily use for at least 2 months, you may not provide adequate time to evaluate effectiveness.

Have Unrealistic Expectations About Research-Stage Peptides: If you expect guaranteed outcomes, dramatic transformations, or miracle cures, you will likely be disappointed. BPC-157 is a research-stage compound with promising preclinical data but limited human clinical evidence. Individual results vary widely, and some users experience no noticeable benefits.

Questions to Ask Yourself Before Ordering:

Have I discussed my tissue support needs with a healthcare provider? Even though BPC-157 is a dietary supplement, responsible use includes informing your physician about all supplements you take, especially if you have chronic health conditions or take medications.

Am I prepared to use this consistently for 2+ months to evaluate effectiveness? Tissue repair processes are gradual. Inconsistent use or expecting results within days will not provide a fair assessment of whether this supplement aligns with your body’s needs.

Do I understand this is a research-stage peptide, not an FDA-approved drug? Clarity about what BPC-157 is—and is not—prevents disappointment and ensures informed decision-making.

Does the oral delivery format fit my lifestyle better than injections? Consider your daily routines, comfort with different administration methods, and lifestyle factors like travel frequency when choosing between oral and injectable options.

Am I comfortable with ProHealth’s quality standards and company background? Review the third-party lab testing protocols, company history, and return policies to ensure they meet your personal standards for supplement sourcing.

Your answers to these questions help determine whether ProHealth BPC-157 represents a logical addition to your wellness approach or whether alternative options better suit your circumstances.

How ProHealth BPC-157 Is Made: What the Company Discloses About Manufacturing

Understanding what companies disclose about manufacturing and quality control processes helps consumers evaluate verification standards in the peptide supplement market.

Synthesis and Formulation: According to the company, ProHealth BPC-157 is described as being synthesized in FDA-registered, GMP-certified facilities with documented testing protocols. The company states it uses the arginate salt form, which the company positions for its potential gastric stability advantages over the acetate salt form commonly used in injectable preparations.

According to the company, each capsule contains 500mcg of BPC-157, providing a standardized dose. The capsule format protects the peptide from premature degradation and allows for precise dosing without measuring or drawing doses as required with injectable formulations.

Triple Third-Party Lab Testing Protocol: According to the company, what distinguishes ProHealth’s quality verification approach is a triple independent testing system. The company states that each batch undergoes three separate rounds of testing at independent third-party laboratories:

Testing Round 1 — Identity Verification: According to the company, this confirms the product contains actual BPC-157 rather than filler or substitute compounds, using analytical techniques like mass spectrometry to verify the molecular structure matches authentic BPC-157.

Testing Round 2 — Purity Analysis: The company states this screens for contaminants including heavy metals (lead, mercury, arsenic, cadmium), microbial pathogens (bacteria, yeast, mold), and residual solvents from manufacturing processes.

Testing Round 3 — Potency Verification: According to company disclosures, this confirms the capsule contains the labeled amount of BPC-157 (500mcg) rather than underdosed or overdosed quantities.

Certificate of Authenticity Access: The company states it provides customers access to view Certificates of Authenticity for their products, allowing verification of testing results rather than relying solely on company claims.

Manufacturing Standards: According to company materials, the company describes manufacturing in facilities that meet Good Manufacturing Practice (GMP) standards as defined by FDA regulations for dietary supplements. The company emphasizes quality verification through independent third-party testing rather than relying solely on manufacturer claims. Always verify current pricing, bundle options, and subscription terms on the official ProHealth website (official ProHealth page) before purchasing.

Pricing and Access: Understanding the Investment Required

Pricing and Access Information:

ProHealth BPC-157 is positioned as a premium oral peptide supplement, with pricing and subscription options listed on the official product page and subject to change. According to the company’s website, the company describes various purchasing options including single bottles and multi-bottle configurations. According to promotional materials, a subscription program is available with reported discounts for recurring shipments.

According to the company’s return policy, purchases are backed by a 100-day money-back guarantee. The company states that customers unsatisfied with the product can return it for full refund even if bottles have been opened and partially used. The extended guarantee period provides customers time to evaluate the product, given that biological processes occur gradually over weeks to months.

Always verify current pricing and terms on the official ProHealth Longevity website before making purchase decisions.

Market Positioning Context:

ProHealth BPC-157 is positioned in the oral peptide supplement category. These options differ primarily in delivery format, access requirements, documentation transparency, and regulatory considerations. Injectable peptide options typically require prescriptions and medical provider relationships. Other oral BPC-157 products vary in their testing documentation and company backgrounds. Conventional tissue support supplements like collagen peptides and joint formulas occupy different market segments with different research bases and regulatory histories.

Realistic Expectations: What ProHealth States vs. What Research Suggests

Setting accurate expectations prevents disappointment and allows for fair assessment of whether BPC-157 provides value for individual users.

What ProHealth States:

According to the company’s product page, BPC-157 is marketed for support of tissue pathways, cellular processes, and biological functions based on preclinical research findings. These claims are positioned as supporting general wellness rather than treating specific medical conditions.

The company emphasizes that BPC-157 is a dietary supplement, not a medication, and that individual responses vary based on numerous factors including age, baseline health status, consistency of use, lifestyle factors, and genetic variables.

What the Preclinical Research Suggests:

Laboratory studies using animal models have examined several biological processes:

Tendon and Ligament Processes: Rodent studies have demonstrated effects in Achilles tendon injury models, with treated animals showing differences compared to controls in controlled laboratory conditions. Human tissue outcomes remain unproven.

Gut-Related Processes: Early research focused on gastric effects in animal models. Clinical relevance for human gut conditions is not established.

Inflammatory Pathways: Research in laboratory settings has examined interactions with inflammatory signaling. Human clinical applications are unproven.

Cellular Processes: Some preclinical studies have examined biological mechanisms in laboratory and animal research settings. Translation to human outcomes is not demonstrated.

These are animal model findings and in vitro studies. They establish biological mechanisms in controlled settings but do not constitute proof of specific human outcomes.

Timeframe Considerations:

The company notes that consistent use over several weeks is typical before users may notice changes, if any occur. This timeframe aligns with the gradual nature of biological processes, which occur over weeks to months, not days.

Some users report subjective changes within 2-3 weeks. Others require 6-12 weeks of consistent use before noticing anything. A subset of users report no noticeable effects even after extended use.

This variability reflects individual biological differences and the research-stage nature of the compound. Supplements with decades of human clinical trials still show response variability; research-stage peptides show even more dramatic individual differences.

What This Product Is NOT:

NOT an FDA-Approved Drug: BPC-157 has not undergone the rigorous clinical trial process required for pharmaceutical approval. It exists as a dietary supplement ingredient with promising preclinical research but without the level of human evidence required for drug status.

NOT a Replacement for Medical Care: Diagnosed medical conditions—chronic tendinitis requiring orthopedic evaluation, inflammatory bowel disease, nerve damage—require care from qualified healthcare providers. BPC-157 is not a substitute for medical treatment of diagnosed conditions.

NOT a Guarantee of Specific Outcomes: No supplement can guarantee results for all users. Individual factors including genetics, baseline health, severity of issues being addressed, lifestyle factors, and consistency of use all affect whether any individual experiences changes, and many users experience no noticeable effects.

NOT Appropriate for Acute Injuries Requiring Medical Intervention: Fractures, severe sprains, traumatic injuries, and conditions requiring immediate medical attention should be evaluated and treated by healthcare professionals. BPC-157 is positioned for wellness support and recovery optimization, not acute medical emergencies.

What Constitutes a Fair Evaluation:

To fairly evaluate whether ProHealth BPC-157 provides value for your specific circumstances:

Consistent Daily Use: The company recommends one capsule daily. Sporadic use or frequent missed doses does not provide adequate assessment of individual response.

Realistic Timeframes: The company notes several weeks of consistent use as typical before changes may be noticed, if any occur. Biological processes are gradual.

Individual Variability: Not every supplement works for every person. The company’s guarantee allows return for refund if no meaningful changes are experienced.

Comparison Context: How ProHealth BPC-157 Positions in the Market

Understanding how ProHealth BPC-157 compares to alternatives helps consumers make informed choices aligned with their priorities. These options differ primarily in delivery format, access requirements, documentation transparency, and regulatory considerations.

vs. Injectable BPC-157:

ProHealth Oral Characteristics:

  • No needles, injections, or sterile technique required
  • Once-daily dosing vs. twice-daily injections typical for injectable protocols
  • No refrigeration needed (capsules stable at room temperature)
  • Convenient for travel and busy schedules
  • Dietary supplement status (no prescription required)

Injectable Characteristics:

  • Potentially higher bioavailability reaching systemic circulation (comparative human data does not exist)
  • Established user base with extensive anecdotal reports
  • Ability to perform local injection near injury sites
  • Dosing protocols from practitioner guidance more available

Consideration: Oral BPC-157 suits needle-averse beginners prioritizing convenience. Injectable suits experienced peptide users working with knowledgeable practitioners.

vs. Collagen Peptides:

BPC-157 Characteristics:

  • More specific mechanism targeting cellular pathways in preclinical research
  • Research-stage peptide with limited human evidence
  • Originally studied for gastric applications in animal models

Collagen Peptide Characteristics:

  • Decades of human research and clinical trials
  • Provides amino acid building blocks
  • Broader evidence base and established safety profile
  • More widely accepted and understood

Consideration: Collagen peptides suit those seeking evidence-based options with established research. BPC-157 suits those willing to explore research-stage compounds.

vs. Compounding Pharmacy Peptides:

ProHealth Characteristics:

  • No prescription or telemedicine consultation required
  • Dietary supplement regulatory category
  • Oral convenience

Compounding Pharmacy Characteristics:

  • Medical supervision and practitioner guidance
  • Injectable delivery
  • Customized dosing based on individual needs
  • Part of comprehensive treatment plan

Consideration: Compounding pharmacy peptides suit those wanting medical supervision. ProHealth suits those preferring self-directed supplementation without prescription requirements.

vs. Other Oral BPC-157 Brands:

ProHealth Differentiators:

  • 36-year company history (not peptide startup)
  • According to the Better Business Bureau, BBB A+ rating and verifiable business legitimacy
  • According to the company, triple third-party lab testing protocols
  • 100-day guarantee (longer than typical 30-60 days)
  • Manufacturing disclosures and quality verification emphasis
  • Viewable Certificates of Authenticity

Other Brand Characteristics:

  • Some may offer different pricing structures
  • Some have more established presence in peptide-specific communities
  • Some offer different formulations (liposomal, sublingual)

Consideration: ProHealth suits consumers prioritizing quality verification, company longevity, and transparent business practices.

vs. Conventional Joint Supplements (Glucosamine, MSM, Chondroitin):

BPC-157 Characteristics:

  • Cellular pathway mechanisms in preclinical research
  • Broader potential applications studied in laboratory settings
  • Research-stage peptide with limited human data

Conventional Supplement Characteristics:

  • Decades of human clinical trials
  • Established safety profiles
  • More widely understood and accepted

Consideration: Conventional supplements suit those preferring established, evidence-based options. BPC-157 suits those who have tried conventional approaches and are willing to explore research-stage alternatives.

The comparison context illustrates that ProHealth BPC-157 occupies a specific market position: oral delivery format, quality verification emphasis, and targeting consumers willing to explore research-stage peptides from established companies with documented testing protocols.

Compliance and Safety Considerations: What Users Should Know

Legal Status and Regulatory Classification:

Regulatory status around peptides continues to evolve, and agencies have issued advisories and taken enforcement actions against peptide-related products depending on claims, intent for human use, and other factors. BPC-157 is not listed in FDA’s approved drugs database, and the Department of Defense’s Operation Supplement Safety (OPSS) cautions consumers about unapproved peptides found in wellness products. Readers should verify the most current guidance and discuss risks with a qualified healthcare professional before using any peptide supplement.

Safety Profile Based on Available Data:

Preclinical safety studies have not identified significant adverse effects from BPC-157 administration in animal models at doses substantially higher than those used in supplementation. The compound has been studied for extended periods in research settings without reported toxicity concerns.

Limited human data exists, but anecdotal reports from the peptide user community generally describe BPC-157 as well-tolerated. Common experiences include no noticeable side effects at standard doses (250-500mcg for injectable, 500mcg for oral).

However, comprehensive long-term human safety data does not exist. BPC-157 is a research-stage compound without the extensive Phase I, II, and III clinical trials that FDA-approved medications undergo. Users accept unknown risks inherent in exploring compounds without complete human safety profiles.

Who Should Exercise Particular Caution:

Pregnant or Nursing Women: No safety data exists for BPC-157 use during pregnancy or lactation. The compound should be avoided during these periods unless specifically recommended by a qualified healthcare provider after careful risk-benefit assessment.

Individuals Taking Medications: While no documented drug interactions exist, anyone taking prescription medications should inform their healthcare provider before adding BPC-157 or any supplement to their regimen. Theoretical interactions could occur with medications affecting blood clotting, immune function, or tissue growth.

People With Cancer History or Active Cancer: Given BPC-157’s potential effects on angiogenesis and cellular proliferation pathways, individuals with cancer history should consult oncologists before use. While no evidence suggests BPC-157 promotes cancer growth, precautionary consultation is appropriate.

Those With Bleeding Disorders: Animal studies suggesting enhanced blood vessel formation and circulation effects warrant caution in individuals with bleeding disorders or taking anticoagulant medications.

Children and Adolescents: BPC-157 has not been studied in pediatric populations. Use in individuals under 18 is not recommended without specific healthcare provider guidance.

Physician Consultation Recommendations:

Any individual with chronic health conditions, taking prescription medications, or managing diagnosed medical issues should disclose BPC-157 use to their healthcare provider. While physicians may not be familiar with research-stage peptides, providing information about what you are taking allows them to monitor for potential interactions or contraindications.

For individuals working with sports medicine physicians, orthopedists, gastroenterologists, or functional medicine practitioners, these providers may have familiarity with peptide therapy and can offer informed guidance on whether BPC-157 fits into comprehensive treatment plans.

Monitoring and Discontinuation:

Users should monitor their response to BPC-157 and discontinue use if any concerning symptoms develop. While serious adverse effects have not been documented, individual sensitivities can occur with any supplement.

If you experience unexpected symptoms after starting BPC-157—whether physical discomfort, unusual fatigue, changes in mood, or any concerning signs—discontinue use and consult a healthcare provider for evaluation.

Drug Testing Considerations:

BPC-157 is on the World Anti-Doping Agency (WADA) Prohibited List under S0 (Non-Approved Substances). Athletes subject to drug testing by WADA-compliant organizations should not use BPC-157, as it is explicitly prohibited in competition and may be prohibited out of competition depending on sport-specific rules. Professional, collegiate, and Olympic athletes risk sanctions, suspension, and eligibility consequences if BPC-157 is detected in drug testing.

Athletes should consult their sport’s governing body and anti-doping authority before considering any peptide supplement. BPC-157’s presence on the WADA Prohibited List makes it inappropriate for tested athletes regardless of its dietary supplement status in the broader consumer market.

Quality and Contamination Concerns:

The peptide supplement market includes products of widely varying quality. Some products marketed as BPC-157 have been found through independent testing to contain little or no actual peptide, instead consisting primarily of filler. This is why ProHealth’s triple third-party lab testing and Certificate of Authenticity transparency matter—they provide verification against the counterfeit and low-quality products flooding the market.

Contact Information: Reaching ProHealth Before or After Purchase

For questions before or during use of ProHealth BPC-157, according to the company’s website, customer support is available through multiple channels:

Phone Support:

  • Toll-Free (US): (800) 366-6056
  • International: (805) 564-3064
  • Hours: Monday through Friday, 8:00 AM to 5:00 PM Pacific Time

Email and Online Contact:

  • Contact forms available through the official ProHealth Longevity website
  • Customer service team typically responds within one business day

Mailing Address: ProHealth, Inc. 1025 Cindy Lane Carpinteria, CA 93013 USA

What Customer Service Can Assist With:

  • Product-specific questions (dosing, formulation, storage)
  • Order status and tracking information
  • Return and refund processing for guarantee claims
  • Subscription management (pause, skip, cancel, modify)
  • Third-party lab certificate access for current batches
  • General company information and policies

The availability of real, responsive customer support through phone lines staffed during business hours distinguishes established supplement companies from drop-shipping operations or fly-by-night peptide vendors with no accessible support infrastructure.

See current availability and detailed specifications on the official ProHealth longevity website (official ProHealth page).

Final Verdict: Evaluating ProHealth BPC-157 for Your Circumstances

After comprehensive analysis of ProHealth BPC-157’s positioning, quality standards, preclinical research basis, practical considerations, and market context, several conclusions emerge for different consumer profiles.

The Case for ProHealth BPC-157:

For individuals seeking to explore oral peptide therapy without injection commitment, ProHealth BPC-157 offers several compelling advantages. The company’s 36-year operational history, A+ Better Business Bureau rating, and transparent business practices provide legitimacy verification in a market often characterized by questionable vendors and unverifiable quality claims.

The triple third-party lab testing protocol addresses the primary concern facing peptide consumers: How do I know this product actually contains what it claims? Independent verification for identity, purity, and potency, with viewable Certificates of Authenticity, provides objective quality confirmation rather than relying solely on manufacturer statements.

The arginate salt formulation reflects informed choice based on gastric stability research, addressing the core technical question of whether oral BPC-157 can survive digestive processes. While bioavailability questions remain incompletely answered, the formulation selection demonstrates attention to scientific considerations rather than arbitrary product development.

For needle-averse individuals, the convenience factor is substantial. Once-daily oral dosing integrates seamlessly into existing supplement routines without the psychological barriers, technical demands, or lifestyle disruptions associated with injection protocols. This accessibility makes peptide therapy exploration viable for a broader population than injectable-only options serve.

The 100-day satisfaction guarantee provides meaningful risk reduction. This extended trial period (versus typical 30-60 day windows) acknowledges that tissue repair processes are gradual and that fair assessment requires adequate time. The guarantee allows users to trial the product with limited financial risk, understanding they can obtain refunds if results do not meet expectations.

Pricing at $50-70 monthly (with subscription) positions ProHealth BPC-157 at approximately 60-75% less cost than injectable peptides obtained through compounding pharmacies while maintaining pharmaceutical-grade quality standards. For budget-conscious consumers, this represents significant value compared to alternative peptide therapy options.

Considerations to Weigh:

BPC-157 remains a research-stage peptide without extensive human clinical trials. The preclinical data is promising, but individual human responses vary dramatically. Some users experience noticeable benefits; others notice minimal or no effects. The compound does not have the evidence base that FDA-approved medications or well-established supplements like collagen peptides possess.

The oral delivery format may have different bioavailability compared to injectable protocols, and dosing equivalency between administration routes is not definitively established through comparative pharmacokinetic studies. Users must accept uncertainty about how much BPC-157 actually reaches systemic circulation when swallowed versus how much is degraded during digestion.

For individuals seeking FDA-approved treatments, guaranteed outcomes, or immediate acute injury intervention, BPC-157 is not the appropriate choice. Medical conditions require medical care from qualified healthcare providers. Research-stage dietary supplements complement wellness approaches but do not replace evidence-based medical treatment.

The premium pricing reflects ProHealth’s quality standards and company positioning. Consumers prioritizing lowest possible cost may find less expensive oral BPC-157 options from newer vendors, though quality verification and company legitimacy vary substantially across the market. The decision becomes whether pharmaceutical-grade standards and established company reputation justify premium pricing.

Important Note on Regulatory Context:

The peptide supplement industry has been under increased regulatory scrutiny in recent years. The FDA has issued guidance documents, warning letters, and taken enforcement actions against companies making inappropriate drug claims or selling adulterated products. Consumers should review the most current information about any peptide product’s compliance and regulatory standing before purchasing.

ProHealth positions BPC-157 as a dietary supplement complying with current regulations, but regulatory landscapes evolve. Staying informed about potential classification changes, regulatory guidance updates, or enforcement actions affecting peptide products helps consumers make decisions based on current rather than outdated information.

Who This Product Suits Best:

ProHealth BPC-157 appears optimally suited for:

Health-conscious adults aged 35-65 experiencing age-related recovery challenges, chronic overuse issues from active lifestyles, or persistent gut health concerns unresponsive to conventional approaches.

Individuals willing to commit to consistent 2+ month use with realistic expectations about gradual tissue repair processes rather than expecting immediate dramatic results.

Consumers comfortable with research-stage ingredients who understand they are exploring cutting-edge supplementation with promising but not definitive human evidence.

Those seeking convenient oral alternatives to injectable peptides who value lifestyle integration and needle-free administration over theoretical bioavailability optimization.

People prioritizing quality verification and company legitimacy who are willing to pay premium pricing for triple third-party lab testing, pharmaceutical-grade manufacturing, and purchasing from an established supplement company with verifiable track record.

For those seeking FDA-approved treatments, immediate medical intervention, or guaranteed outcomes, conventional medical care remains the appropriate path. BPC-157 occupies a specific niche for proactive individuals exploring cutting-edge wellness supplementation as part of comprehensive health optimization strategies.

The decision to try ProHealth BPC-157 ultimately depends on individual circumstances, health goals, risk tolerance, and whether the specific advantages this product offers—oral convenience, quality verification, established company reputation—align with personal priorities and wellness philosophy.

Disclaimers

Content and Educational Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. BPC-157 is a research-stage peptide without extensive human clinical trials. The descriptions of potential benefits are based on preclinical research and are not guarantees of individual results. ProHealth BPC-157 is a dietary supplement, not an FDA-approved drug. Always consult a qualified healthcare professional before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Professional Medical Disclaimer: This article is educational and does not replace professional medical guidance. BPC-157 is not a substitute for prescribed medical treatment. If you are managing chronic injuries, gut health issues, or any medical condition, consult your physician before using BPC-157 or any supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s approval.

Research Status Disclaimer: BPC-157 research is primarily based on preclinical animal models and in vitro studies. Human clinical trial data is extremely limited. This is ingredient-level research; ProHealth BPC-157 as a finished product has not been clinically studied in humans. Individual results will vary based on factors including age, baseline health condition, consistency of use, genetic factors, and other individual variables.

Results May Vary: Individual experiences with BPC-157 vary widely. While some users report benefits within weeks, others require longer timeframes or experience no noticeable changes. Results are not guaranteed. Factors affecting individual response include baseline tissue health, severity of issues being addressed, consistency of use, lifestyle factors, current medications, and genetic variables.

FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All opinions and descriptions are based on preclinical research, publicly available information, and the company’s published materials.

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were accurate at the time of publication (December 2025) but are subject to change without notice. ProHealth may modify pricing, subscription terms, bundle options, and promotional offers at any time. Always verify current pricing and terms on the official ProHealth Longevity website before making your purchase.

Publisher Responsibility: The publisher of this article has made every effort to ensure accuracy at the time of publication based on preclinical research, company-provided information, and publicly available data. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with ProHealth and their healthcare provider before making decisions.

Regulatory Disclaimer: The peptide supplement industry has been subject to regulatory scrutiny. BPC-157’s legal status and regulatory classification may evolve. Consumers are responsible for staying informed about current regulations and ensuring compliance with all applicable laws in their jurisdiction.

Not a Replacement for Medical Treatment: BPC-157 is not intended to diagnose, treat, cure, or prevent any disease. This supplement is not a replacement for medical treatment of injuries, gut conditions, or any diagnosed medical issue. Anyone with chronic health concerns should work with qualified healthcare professionals for comprehensive care.

Contact Information: ProHealth, Inc. 1025 Cindy Lane Carpinteria, CA 93013 Phone: (800) 366-6056 | International: (805) 564-3064 Hours: Monday-Friday, 8:00 AM – 5:00 PM Pacific Time

For more information: Visit ProHealth Longevity

CONTACT: CustomerLoyalty@prohealth.com
Phone: (800) 366-6056 | International: (805) 564-3064 Hours: Monday-Friday, 8:00 AM - 5:00 PM Pacific Time

Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn




Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

Seasoned executive brings four decades of finance, capital markets, and life sciences experience

DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelthos’ 2026 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation or removal. Also, effective immediately, Mr. Einhorn will also serve on the Audit Committee and the Compensation Committee of the Pelthos Board of Directors.

Mr. Einhorn brings extensive corporate financial management experience to the role, with more than four decades of experience in investment banking and capital markets, as well as in C-level finance roles at fast-paced clinical and commercial-stage life science companies.

“Andrew’s extensive capital markets and in-house finance experience make him a strong addition to the Pelthos Board of Directors,” said Peter Greenleaf, Chairman of the Board. “His experience accelerating company growth at multiple public and private life science companies will be critical as Pelthos grows as a commercially focused company.”

With the addition of Mr. Einhorn, the Pelthos Board has increased to eight directors.

Mr. Einhorn currently serves as a consultant at Danforth Advisors, providing high-level strategic financial guidance to public and private life science companies. Before joining Danforth, Mr. Einhorn served as Chief Financial Officer at multiple clinical and commercial-stage biotechnology companies, including ESP Pharma, Esprit Pharma, Oceana Therapeutics, Edge Therapeutics and RVL Pharmaceuticals, over his 20-year tenure in the industry. He previously worked in capital markets and investment banking for more than 20 years. He currently serves as a venture advisor to the Israel Biotech Fund.

“I am excited to work alongside this distinguished group of industry executives to help guide Pelthos in my new role on Pelthos’ Board of Directors,” said Mr. Einhorn. “I believe Pelthos is already off to a strong start as a new publicly traded company, and I look forward to collaborating with the Board of Directors to enhance the Pelthos mission for the bright future ahead.”

About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) Mr. Einhorn’s capital markets and in-house finance experience making him a strong addition to the Pelthos Board of Directors, (ii) the impact Mr. Einhorn’s experience accelerating company growth at multiple public and private life science companies will have on Pelthos as it grows as a commercially focused company, and (iii) Mr. Einhorn’s belief that Pelthos is already off to a strong start as a new publicly traded company and his expectations with respect to enhancing the Pelthos mission in the future. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to our reliance on third-party partners for market access and distribution; the possibility that ZELSUVMI may not achieve market acceptance or broad formulary coverage; our ability to maintain regulatory approvals; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change




Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

RAMAT GAN, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, announced today that following the approval of its shareholders on November 10, 2025, its Board of Directors has approved a 1-for-3,000 reverse split of the Company’s  ordinary shares. The reverse split will be recorded with the Tel-Aviv Stock Exchange  on January 2, 2026 and on January 4, 2026, the Tel-Aviv Stock Exchange will be closed. The first trading date for the newly consolidated ordinary shares on the Tel-Aviv Stock Exchange will be January 5, 2026.

The reverse split will result in each outstanding three thousand pre-split ordinary shares automatically combining into one new ordinary share, no par value, without any further action on the part of the shareholders. Concurrently with the reverse split, the Company will effect a corresponding change in the ratio of ordinary shares underlying each of the Company’s American Depositary Shares (ADSs), such that its ratio of ADSs to ordinary shares will change from one (1) ADS representing three hundred (300) ordinary shares to a new ratio of one (1) ADS representing two (2) ordinary shares and no adjustment will be made to the outstanding number of the ADSs of the Company. The ratio change will be effective on the NYSE American on January 5, 2026.

For ADS holders, the ratio change will have the same effect as a one-for-twenty ADS split. On the effective date, each ADS holder will be required to exchange every twenty (20) ADSs then held for one (1) new ADS. The Bank of New York Mellon, the depositary bank, will arrange for the exchange of the current ADSs for the new ones. The Company’s ADSs will continue to trade on the NYSE American under the symbol “CANF” with a new CUSIP Number 13471N409.

The total number of outstanding ordinary shares will be reduced on the effective date at a ratio of three thousand-for-one. The Company’s authorized number of ordinary shares will also be proportionately decreased from 42,000,000,000 to 14,000,000 ordinary shares, no par value, each as a result of the reverse split. No fractional ordinary shares will be issued as a result of the reverse split as any fractional ordinary shares resulting from the reverse split will be rounded up to the nearest whole share on a per shareholder basis.

The reverse split and ADS ratio change will not impact any shareholder’s percentage ownership of the Company or voting power, except for minimal effects resulting from the treatment of fractional shares.

No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank.

As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although the Company can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than twenty times the ADS price before the change. 

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on April 7, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contact

Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114

Organogenesis Announces Initiation of Biologics License Application for ReNu®

Organogenesis Announces Initiation of Biologics License Application for ReNu®




Organogenesis Announces Initiation of Biologics License Application for ReNu®

Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026

CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for ReNu,® a cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee arthritis. Organogenesis plans to complete the BLA submission with the final modules submitted in the first half of 2026.

“This is another significant achievement for the ReNu clinical development program and a pivotal moment for Organogenesis,” said Patrick Bilbo, Chief Operating Officer of Organogenesis. “If approved, ReNu would be the first non-surgical biologic therapy to address knee osteoarthritis pain for all patients, especially for those classified as most severe.”

Knee OA is a degenerative joint disease that is estimated to affect nearly 31.1 million Americans and projected to grow to 34.4 million Americans by 2027. It is ranked among the most common causes of disability and poor quality of life, generally characterized by pain and functionality deficits. End stage management of the disease in these patients is typically a total knee replacement when all other treatment options are exhausted.

About ReNu®
ReNu is a cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee osteoarthritis. ReNu consists of amniotic fluid cells and micronized amniotic membrane and contains cellular, growth factor, and extracellular matrix components. ReNu has been studied in three large RCTs consisting of more than 1,300 patients and received FDA RMAT designation for Knee OA in 2021. ReNu was previously marketed under Section 361 of the Public Health Service Act and was commercially available for approximately six years.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.  

Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “planned,” “intend,” “seek,” “anticipate,” “believe,” “expect,” “estimate,” “potential” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, including statements regarding the anticipated timing of regulatory submissions and interactions. These statements concern, and these risks and uncertainties include, among others: the risks and uncertainties inherent in clinical development; determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to develop or commercialize ReNu; the timing of our submissions to the FDA; the likelihood and timing of possible regulatory approval and commercial launch of ReNu; the FDA may conclude the data we submit for ReNu is not sufficient for BLA approval; the FDA may require additional evidence for ReNu before we can get a BLA approved, which we may not be able to obtain; that other clinical trials of ReNu may produce different results; ongoing regulatory obligations and oversight impacting ReNu; unforeseen safety issues resulting from the administration of ReNu in patients; competing products and product candidates that may be superior to our products and product candidates; uncertainty of market acceptance and commercial success of ReNu and the impact of studies (whether conducted by us or others and whether mandated or voluntary) on the commercial success of ReNu; our ability to manufacture and manage supply components for ReNu; the availability and extent of reimbursement of ReNu from third-party payers, including private payer healthcare and insurance programs and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers, including local coverage determinations by Medicare Part A/B Medicare Administrative Contractors; new policies and procedures adopted by such payers; unanticipated expenses; the costs of developing, producing, and selling ReNu; our ability to meet our sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance;  and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2024 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. 

CONTACT: Investor Inquiries: ICR Healthcare Mike Piccinino, CFA OrganoIR@westwicke.com 
Press and Media Inquiries: Organogenesis Communications@organo.com

Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche

Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche




Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR 
FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) — Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces an increase to its non-brokered private placement financing, previously announced on November 6, 2025, to $750,000 and the closing of the third tranche (the “Third Tranche”). Gross proceeds from the Third Tranche totaled CAD $352,500 from the sale of 5,035,714 units (the “Units”) at an issue price of CAD $0.07 per Unit. The closing of the Third Tranche brings the financing to a total of CAD $739,500 from the sale of 10,564,286 Units, including the closing of the first and second tranches on November 14, 2025 and November 28, 2025, respectively.

The Company did not pay any cash finder’s fees pertaining to the Third Tranche of the Offering.

The Company will use the proceeds of the Offering towards advancing its Alzheimer’s Disease (“AD”) program including the opening of its first U.S. AD clinic, general and administrative expenses and for working capital purposes.

The securities issued and issuable, described in this and the previous news release on November 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration

For more information please contact:

Christopher J. Moreau
CEO
Algernon Health Inc.
604.398.4175 Ext 701
cjmoreau@algernonhealth.com

https://www.algernonhealth.com/ 

About Algernon Health  

Algernon Health is a Canadian healthcare company focused on the provision of brain optimized PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s Disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a recently created private subsidiary called Algernon USA LLC, that will oversee all U.S. neuroimaging operations.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to planned brain-specific neuroimaging PET scanning clinic opening timelines, planned financings in the Company and its subsidiary and the closings of additional tranches thereof, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors

Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors




Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors

BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) — Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company’s recently announced $150M PIPE financing, which included participation from both investors.

“Andrew and Wouter bring highly complementary experience in life sciences investment, financing strategy, and board-level oversight. We are delighted to welcome them to our Board at an important moment for the Company,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. “Their perspectives will be invaluable as we advance our global Phase 3 programs and position the Company to drive long-term shareholder value.”

Dr. Levin is a Partner on the investment team at RA Capital Management, L.P., where he brings deep expertise in life sciences investing and strategic oversight to support innovative biopharma companies across all stages of development. He holds a B.S. in mechanical engineering from Princeton University, and M.D. from Harvard Medical School, and a Ph.D. in biomedical engineering from Massachusetts Institute of Technology. Dr. Levin fills the seat previously held by Sarah Reed, General Counsel at RA Capital, who resigned from the Board.

“Vor Bio is at an important inflection point, and I am excited to support the Company as it advances telitacicept through global Phase 3 development and continues to focus on disciplined capital allocation and long-term growth,” said Dr. Levin.

Mr. Joustra is a General Partner at Forbion, where he is responsible for general fund management, late stage private, cross-over and public investments.   Mr. Joustra has served on the boards of several high-growth biotech companies through successful acquisitions and currently serves on the boards of multiple public and private life sciences companies. He holds an M.Sc. in Business Administration and a B.Sc. in International Business and Management from the University of Groningen.

“Vor Bio has established an exceptionally strong foundation with telitacicept, and I look forward to contributing my experience in late-stage biotech growth and value creation as the Company scales its clinical programs,” said Mr. Joustra.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding Vor Bio’s development plans for telitacicept; and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

Singlera Genomics Signs European Distribution and Research Agreement with Pure Medical for Cancer Detection Products

Singlera Genomics Signs European Distribution and Research Agreement with Pure Medical for Cancer Detection Products




Singlera Genomics Signs European Distribution and Research Agreement with Pure Medical for Cancer Detection Products

LA JOLLA, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) — Singlera Genomics, a company focused on the development and application of novel DNA methylation technologies to genetic diagnosis, today announced that it has entered into a research and distribution agreement with European Union-based international medical company Pure Medical.

Singlera’s mTitan and mGuard platforms screen circulating cell-free DNA for signals associated with cancer, often before symptoms appear. The patented technology behind these platforms has been utilized to non-invasively detect methylation haplotypes from esophageal, colorectal, gastric, lung, liver, and pancreatic cancer. Under the terms of the agreement, Singlera and Pure Medical will collaborate with local universities, hospital networks, and national heathcare systems on research studies across western Europe, as well as on the commercial distribution of mTitan- and mGuard-based assays in several European countries.

“We are excited to partner with Pure Medical to focus on cancer detection and surveillance across western Europe, including colorectal and pancreatic cancer,” said Qiang Liu, COO and co-founder of Singlera Genomics. “This distribution agreement represents an important step in our European business strategy to bring inexpensive early cancer detection and monitoring to the global patient population; we hope that Singlera’s methylation products can give clinicians an important tool for faster detection, diagnosis, and treatment of cancer.”

“We are pleased to be working with Singlera Genomics,” said Maarten van Dijk, CEO of Pure Medical. “We are already engaged in research collaborations with academic and healthcare institutions across the UK and Europe, and are working toward the earliest possible commercialization of Singlera’s colorectal and pancreatic cancer products across seven EU countries. These innovative, non-invasive technologies have the potential to support earlier detection and more effective monitoring of colorectal and pancreatic cancer, and we are encouraged by what our existing engagement with healthcare systems can bring in translating this innovation into real-world clinical benefit.”

Singlera Genomics Inc. (www.singlera.com)

Singlera Genomics Inc., a globally operating enterprise specializing in non-invasive genetic diagnosis, was established in July 2014. With a presence spanning across continents, the company boasts research and development centers along with business operations worldwide. Singlera is at the forefront of innovation with its proprietary technologies in single-cell sequencing, DNA methylation, and bioinformatics, making significant strides in the global field of genomics.

Pure Medical (www.puremedical.world)

Founded in 2015, Pure Medical is an established international medical company with a strong background in genetics. The company works closely with innovative healthcare specialists, governments, and medical professionals to address both current and future healthcare challenges. Pure Medical focuses on supporting the introduction and adoption of new medical technologies within national healthcare systems. Through strategic partnerships and a commitment to innovation, Pure Medical aims to improve patient outcomes and enable more effective, accessible, and sustainable healthcare.

Media Contact
858.732.0061
info@singleragenomics.com

Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan

Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan




Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan

Ghent, Belgium, Dec. 23, 2025 (GLOBE NEWSWIRE) — Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan

PRESS RELEASE 
REGULATED INFORMATION / INSIDE INFORMATION
23 December 2025, 6:30 pm CET / 12:30 pm ET 

  • Letter of intent to amend the loan from funds managed by Kreos, including an extension of the interest only period and deferral of amortization payments
  • Additional runway supports ongoing alfapump commercial rollout in the U.S.

Ghent, Belgium – 23 December 2025 Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced that it entered into a non-binding letter of intent with Kreos Capital VII (UK) Limited (together with its affiliates, “Kreos”)1 to agree to a number of amendments to the terms of its loan (the “Kreos Loan“), including notably that the interest only period will be extended, and amortisation repayments will be postponed until 1 May 2026, and that the first two monthly repayments of principal and interest following the new amortisation resumption date (i.e., the 1 May and 1 June payments) shall equal half of each of the monthly repayments of principal and interest for the remaining three (3) months of amortisation to the final repayment date of 1 September 2026. The amendments are subject to the entry into a final binding agreement with Kreos. As a result of converting a portion of the Kreos Loan into equity of the Company during 2025, the outstanding principal of the loan has been reduced to less than €4.5 million.

Ian Crosbie, Chief Executive Officer at Sequana Medical, commented: “We are very pleased with the ongoing support from Kreos as we continue the rollout of alfapump in the US. With these positive steps to improve our financial flexibility, we look forward to building upon our commercial momentum including the recent implants at Mount Sinai and University of Pennsylvania. As we expand our commercial activities, we grow ever more confident of the US market opportunity for alfapump, as obesity drives strong growth in recurrent and refractory ascites due to liver cirrhosis.”

For more information, please contact:

Sequana Medical
Investor relations
E: IR@sequanamedical.com
T: +44 (0) 797 342 9917

Media Relations:
Josephine Galatioto
ICR Healthcare
E: Sequana@icrhealthcare.com
T: +1 (332) 242-4388

About Sequana Medical

Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. This causes major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, intolerable or exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing “diuretic resistant” patient population. alfapump® and DSR® are Sequana Medical’s proprietary platforms that work with the body to treat diuretic-resistant fluid overload, and are intended to deliver major clinical and quality of life benefits for patients, while reducing costs for healthcare systems.

The Company received US FDA approval for the alfapump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough Device Designation in 2019. In Sequana Medical’s POSEIDON study, a landmark study across 18 centers in the US and Canada, the pivotal cohort of 40 patients implanted with the alfapump showed at 6 and 24 months post-implantation the virtual elimination of therapeutic paracentesis and an improvement in quality of life1, 2.

Sequana Medical is commercializing the alfapump through a specialty commercial team initially targeting US liver transplant centers – 90 of these centers perform more than 90% of US liver transplants annually. In August 2025, CMS announced that it approved the New Technology Add-on Payment for the alfapump when performed in the hospital inpatient setting as of October 1, 2025.

Results of the Company’s RED DESERT and SAHARA proof-of-concept studies in heart failure published in European Journal of Heart Failure in April 2024 support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements.3 The independent Data Safety Monitoring Board approved the start of the randomized MOJAVE cohort of up to a further 30 patients, which is dependent on securing additional financing.

Sequana Medical is listed on the regulated market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

Important Safety Information: For important safety information regarding the alfapump® system, see https://www.sequanamedical.com/wp-content/uploads/ISI.pdf.

The alfapump® System is currently not approved in Canada.

DSR® therapy is still in development and is currently not approved in any country. The safety and effectiveness of DSR® therapy has not been established.

Note: alfapump® and DSR® are registered trademarks.

Forward-looking statements

This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.


1         BlackRock Inc. announced the completion of its acquisition of Kreos, a leading provider of growth and venture debt financing to companies in the technology and healthcare industries, on 2 August 2023


1 alfapump system SSED (summary of safety and effectiveness) PMA 230044

2 as defined by subjective physical health (assessed by SF-36 PCS) and ascites symptoms (assessed by Ascites Q)

3 Data reported in press release of March 25, 2024; mean increase of 326% in six-hour urinary sodium excretion at 3 months follow up vs baseline, and 95% reduction of loop diuretics over same period

Attachments

West Hollywood Orthodontist Launches Free ‘Student Airway Baseline’ Screenings After Research Links Sleep-Disordered Breathing to Academic Struggles

West Hollywood Orthodontist Launches Free ‘Student Airway Baseline’ Screenings After Research Links Sleep-Disordered Breathing to Academic Struggles




West Hollywood Orthodontist Launches Free ‘Student Airway Baseline’ Screenings After Research Links Sleep-Disordered Breathing to Academic Struggles

Harvard-trained orthodontist offers complimentary 15-minute airway analysis to help identify hidden causes of childhood focus problems

LOS ANGELES, Dec. 23, 2025 (GLOBE NEWSWIRE) — McComb Orthodontics, a specialty orthodontic practice serving Culver City and West Hollywood, has launched a free screening program designed to identify airway obstructions that research increasingly links to attention deficits and poor academic performance in children.

The “Student Airway Baseline” initiative offers complimentary 15-minute analyses of the orofacial structures for children ages 6 to 12. The program, which requires no referral, aims to detect signs of sleep-disordered breathing before the condition affects school performance or leads to misdiagnosis of behavioral disorders.

“Many parents hire tutors or seek medication for a child who can’t focus, not realizing the child is physically exhausted from poor sleep,” said Dr. Ryan McComb, the Harvard-trained orthodontist who leads the practice. “New research confirms that narrow palates and restricted airways don’t just affect teeth—they can deprive the developing brain of the deep, restorative sleep essential for learning and memory consolidation.”

The initiative follows mounting clinical evidence connecting airway health to cognitive development. A January 2024 systematic review and meta-analysis published in BMC Pediatrics quantified the proportion of neurobehavioral impairments attributed to sleep-disordered breathing in children and adolescents. A separate 2022 meta-analysis in Sleep Medicine Reviews reviewing 77 studies found that children with sleep-disordered breathing had significant impairments across all cognitive domains, with the largest deficits in verbal and overall intelligence.

Airway-Orthodontist-West-Hollywood-McComb

The American Academy of Pediatrics’ September 2025 clinical report on developmental screening emphasizes the critical importance of early identification of conditions that affect mental, emotional, and behavioral health in children, noting that standardized screening helps reduce cognitive biases that can contribute to misdiagnosis.

Sleep-disordered breathing in children often goes undetected because symptoms differ from those in adults. Rather than loud snoring, affected children may exhibit restless sleep, mouth breathing, bedwetting, or daytime behaviors that mimic attention deficit hyperactivity disorder. Studies suggest that as many as one in 10 children experience some form of sleep-disordered breathing, with many cases remaining undiagnosed until problems manifest academically or behaviorally.

“We’re seeing children labeled as problem students when the real issue is that their airway is so compromised they’re operating on a fraction of the sleep their brains need,” Dr. McComb said. “A simple screening can identify structural issues that, when addressed early, may prevent years of struggle in the classroom and at home.”

The noninvasive Student Airway Baseline screening takes approximately 15 minutes and produces immediate results. Children identified with potential concerns receive detailed findings that parents can share with pediatricians or sleep specialists for further evaluation, along with potential referral to ENT specialists.

“This isn’t a dental exam—it’s a baseline measurement that gives families objective data about their child’s airway development,” Dr. McComb said. “Our goal is early identification, before grades suffer and before a child begins to see themselves as someone who can’t succeed in school.”

The complimentary screenings are available at both McComb Orthodontics locations in Culver City and West Hollywood and are open to all students in the greater Los Angeles area regardless of whether they are existing patients. Parents may schedule appointments by contacting either clinic directly or through the practice website.

About McComb Orthodontics

McComb Orthodontics is a specialty orthodontic practice with clinics in West Hollywood, and Culver City, serving families across the Westside and central Los Angeles. The West Hollywood clinic is convenient to Beverly Grove, Melrose, the Fairfax District and the Sunset Strip. The Culver City clinic serves the Culver Arts District, Palms, Mar Vista, Playa Vista and Baldwin Hills. Led by Board Certified orthodontist Ryan McComb, DMD, MS, the practice provides comprehensive care that includes growth and airway-aware evaluations, braces and clear aligners for children, teens and adults. Learn more at https://mccomborthodontics.com/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ce1d3a7-31ce-420c-adb4-bc075f376aa3

CONTACT: Media Contact: Alexandre@McCombortho.com 

Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure

Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure




Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure

CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that it has entered into warrant exchange agreements, subject to customary closing conditions, with holders representing approximately 83.4% of its outstanding Class A and Class B warrants, pursuant to a voluntary warrant exchange program designed to simplify the Company’s capital structure and materially reduce potential future dilution.

The warrant exchange program was developed based on investor feedback and following discussions with several of the Company’s largest institutional shareholders, who expressed strong support for consolidating legacy warrant instruments into a cleaner capital structure.

Background and Participation

In connection with the Company’s prior financing in October 2025, 2,722,642 Class A ordinary shares were issued, with one Class A warrant and one Class B warrant issued for each such Class A ordinary share, for a total of 5,445,284 warrants.

As of the date of this announcement, the Company has entered into exchange agreements covering 4,539,722 of the 5,445,284 aggregate Class A and Class B warrants, representing approximately 83.4% participation.

Summary of the Warrant Exchange

Under the exchange agreements:

  • One (1) Class A warrant and one (1) Class B warrant with exercise prices of $24.12 and $32.16, respectively, each with a five-year term have been exchanged for
  • One (1) new Class C warrant with:
    • an exercise price of $18.00 per Class A ordinary share,
    • a two-year term commencing upon the effectiveness of a registration statement on Form F-3 registering the resale of the shares issuable upon exercise of the Class C warrants, and
    • a standard forced-redemption (call) feature.

The Company may exercise its forced-redemption right only after the registration statement on Form F-3 registering the resale of the shares issuable upon exercise of the Class C warrants is declared effective and only if the Company’s Class A ordinary shares trade at or above 120% of the exercise price (i.e., $21.60) for ten (10) consecutive trading days.

Warrant holders participated in the exchange on a voluntary basis, and identical terms were offered to all eligible warrant holders.

Impact on Capital Structure

Based on the exchange agreements, a total of approximately 4.54 million in aggregate of the Company’s outstanding Class A warrants and Class B warrants is expected to be exchanged for approximately 2.27 million Class C warrants.

After such exchange, the total number of outstanding Class A warrants, Class B warrants and Class C warrants is expected to be approximately 3.18 million in aggregate, representing a reduction of approximately 42.0% from the number of Class A and Class B warrants issued in the October 2025 financing round, and further up to 50% assuming participation in full by all holders of Class A warrants and Class B warrants.

The Company believes this reduction materially improves its long-term dilution profile, reduces warrant overhang, and enhances the investability of its ordinary shares. The Company is not undertaking this warrant exchange in connection with any financing transaction and has no plans to conduct any equity or equity-linked capital raise in the foreseeable future.

Strategic Rationale and Benefits

The Company believes this warrant exchange delivers several meaningful benefits to the Company and its shareholders, including:

  • Up to 50% reduction from the number of outstanding Class A warrants and Class B warrants, materially lowering long-term dilution risk
  • Substantial elimination of two deep out-of-the-money legacy classes of warrants, reducing up to 50% of the overhang on the Company’s shares that resulted from the Class A warrants and Class B warrants
  • Simplification in favor of a single, unified class of warrants, improving transparency and institutional investability
  • Improved alignment with shareholders, by providing a more realistic and attainable path to warrant redemption

The Company noted that its largest institutional investors, each with significant long-term investments, have participated in the exchange, reflecting strong confidence in the revised structure and its long-term benefits.

About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka. IM8 has achieved the fastest growth trajectory in supplement industry history, reaching $100 million+ in ARR within 11 months of launch, outpacing even leading AI startups.

About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.

Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us

Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com

Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance (including warrant structure, numbers and timeline) reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to factors beyond the Company’s control that prevent the closing and final consummation of the exchange agreements. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.